<DOC>
	<DOCNO>NCT01642433</DOCNO>
	<brief_summary>The likely outcome smoke cessation attempt relapse , underscore need advance novel treatment . Preclinical research show noradrenergic system critical modulate drug-seeking behavior recent finding indicate Î±1-adrenergic antagonist prazosin reduces nicotine self-administration reinstatement . Presently , data prazosin 's effect nicotine-related behaviour human lack . An efficient method screen novel smoke cessation medication integrate human laboratory paradigm context brief , randomize trial smoke cessation include smoker motivate quit . This study aim provide initial test prazosin smoke cessation implement brief , randomize trial include human laboratory clinical phenotype . This approach allow efficient sensitive method medication screen maximizes clinical validity .</brief_summary>
	<brief_title>Prazosin Smoking Cessation</brief_title>
	<detailed_description />
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Prazosin</mesh_term>
	<criteria>Greater equal 10 cigarette per day past year Baseline Fagerstrom Test Nicotine Dependence ( FTND ) score great equal four Willing engage two practice quit attempt Willingness forgo medication base treatment trial Current illicit drug use Current treatment psychiatric medication selective serotonin reuptake inhibitor ( SSRIs ) Lifetime diagnosis posttraumatic stress disorder ( PTSD ) Significant medical/neurological illness Baseline BP outside normal range Current use tobacco aid Current use medication could interact prazosin Pregnancy nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>